MVCD2
MCID: MCR112
MIFTS: 22

Microvascular Complications of Diabetes 2 (MVCD2) malady

Categories: Genetic diseases, Nephrological diseases, Cardiovascular diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 2

Aliases & Descriptions for Microvascular Complications of Diabetes 2:

Name: Microvascular Complications of Diabetes 2 54 66 29 13
Proliferative Diabetic Retinopathy 66 69
Diabetic Nephropathy 66 69
Diabetic End-Stage Renal Disease 66
Mvcd2 66

Classifications:



External Ids:

OMIM 54 612623
MeSH 42 D048909

Summaries for Microvascular Complications of Diabetes 2

UniProtKB/Swiss-Prot : 66 Microvascular complications of diabetes 2: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 2, also known as proliferative diabetic retinopathy, is related to microvascular complications of diabetes 1 and microvascular complications of diabetes 3. An important gene associated with Microvascular Complications of Diabetes 2 is EPO (Erythropoietin). The drugs Isosorbide Dinitrate and Nitric Oxide have been mentioned in the context of this disorder.

Description from OMIM: 612623

Related Diseases for Microvascular Complications of Diabetes 2

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 7
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 5 Microvascular Complications of Diabetes 3

Diseases related to Microvascular Complications of Diabetes 2 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 11.3
2 microvascular complications of diabetes 3 11.3
3 epidural abscess 9.8
4 kidney disease 9.8
5 peritonitis 9.8

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 2:



Diseases related to Microvascular Complications of Diabetes 2

Symptoms & Phenotypes for Microvascular Complications of Diabetes 2

Clinical features from OMIM:

612623

Drugs & Therapeutics for Microvascular Complications of Diabetes 2

Drugs for Microvascular Complications of Diabetes 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
2
Nitric Oxide Approved Phase 4 10102-43-9 145068
3
Insulin Glargine Approved Phase 4 160337-95-1
4
Insulin Lispro Approved Phase 4 133107-64-9
5
Zinc Approved Phase 4,Phase 3,Phase 1 7440-66-6 32051 23994
6
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
7
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
8
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
9
Eplerenone Approved Phase 4,Phase 3 107724-20-9 150310 443872
10
Spironolactone Approved Phase 4,Phase 3 1952-01-7, 52-01-7 5833
11
Gliclazide Approved Phase 4 21187-98-4 3475
12
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
13
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
14
Ranibizumab Approved Phase 4 347396-82-1 459903
15 diuretics Phase 4,Phase 3
16 Isosorbide Phase 4
17 isosorbide-5-mononitrate Phase 4
18 Natriuretic Agents Phase 4,Phase 3
19 Nitric Oxide Donors Phase 4
20 Vasodilator Agents Phase 4
21 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1
22 insulin Phase 4,Phase 3,Phase 2
23 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2
24 Antimetabolites Phase 4,Phase 3,Phase 2
25 Atorvastatin Calcium Phase 4 134523-03-8
26 Calcium, Dietary Phase 4
27 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
28 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
29 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
30 Insulin, Isophane Phase 4
31 Isophane insulin, beef Phase 4
32 Isophane Insulin, Human Phase 4
33 Anti-Arrhythmia Agents Phase 4,Phase 3
34 Immunosuppressive Agents Phase 4,Phase 3
35 Anticholesteremic Agents Phase 4
36 Hemostatics Phase 4
37 Diuretics, Potassium Sparing Phase 4,Phase 3
38 Hormone Antagonists Phase 4,Phase 3
39 Hormones Phase 4,Phase 3,Phase 2
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
41 Mineralocorticoid Receptor Antagonists Phase 4,Phase 3
42 Mineralocorticoids Phase 4,Phase 3
43 Cholestyramine Resin Phase 4
44 Antiparkinson Agents Phase 4
45 Dopamine Agents Phase 4,Phase 2
46 Dopamine agonists Phase 4
47 Neurotransmitter Agents Phase 4,Phase 2
48 Angiogenesis Inhibitors Phase 4
49 Angiogenesis Modulating Agents Phase 4
50 Omega 3 Fatty Acid Nutraceutical Phase 4

Interventional clinical trials:

(show top 50) (show all 102)
id Name Status NCT ID Phase
1 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
2 Glargine Versus NPH in Patients With Chronic Kidney Disease Completed NCT02451917 Phase 4
3 Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study) Completed NCT00562172 Phase 4
4 Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes Completed NCT00191464 Phase 4
5 Making Ramadhan Fasting a Safer Experience With Technology Study Completed NCT02189135 Phase 4
6 Pioglitazone Versus Metformin in Type 2 Diabetes Completed NCT00815399 Phase 4
7 Treatment Effects of Atorvastatin on Hemostasis and Skin Microcirculation in Patients With Type 1 Diabetes Completed NCT01497912 Phase 4
8 Lovaza® and Microvascular Function in Type 2 Diabetes Completed NCT00931879 Phase 4
9 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Recruiting NCT02249897 Phase 4
10 Renoprotective Effects of Dapagliflozin in Type 2 Diabetes Recruiting NCT02682563 Phase 4
11 Aldosterone Antagonism and Microvascular Function Recruiting NCT01887119 Phase 4
12 Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Recruiting NCT02682901 Phase 4
13 CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea Recruiting NCT02874313 Phase 4
14 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Not yet recruiting NCT02834663 Phase 4
15 Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients Terminated NCT00961207 Phase 4
16 Genetic Variation in OCT1 and Response to Metformin Withdrawn NCT00588172 Phase 4
17 Diabetes Prevention Program Outcomes Study Unknown status NCT00038727 Phase 3
18 A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus Unknown status NCT01245166 Phase 3
19 A Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Fenofibrate Versus Placebo on Macular Thickness and Volume Unknown status NCT01320345 Phase 3
20 Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) Completed NCT00032487 Phase 3
21 Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Completed NCT00081328 Phase 3
22 The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial Completed NCT00375388 Phase 3
23 OatMeal and Insulin Resistance: OMA-IR Completed NCT00401453 Phase 3
24 Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus Completed NCT00297401 Phase 3
25 The Vascular Effects of Vildagliptin in Insulin Resistant Individuals Completed NCT01122641 Phase 3
26 Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy Completed NCT00556465 Phase 2, Phase 3
27 Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease Completed NCT01574820 Phase 3
28 Electromagnetic Stimulation (FREMS) in Patients With Painful Diabetic Neuropathy Completed NCT00337324 Phase 2, Phase 3
29 Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size Completed NCT01882179 Phase 3
30 The Efficacy of Bariatric Surgery Compared to Medical Therapy in Controlling Type2 Diabetes Mellitus in Patients With Non Morbid Obesity. Recruiting NCT02036138 Phase 2, Phase 3
31 Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients . Active, not recruiting NCT02387749 Phase 2, Phase 3
32 Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes Not yet recruiting NCT02895113 Phase 3
33 Arginase Inhibition and Microvascular Endothelial Function in Type 2 Diabetes Completed NCT02687152 Phase 1, Phase 2
34 Effects of Vitamin B1 in Type 1 Diabetic Patients Completed NCT00117026 Phase 1, Phase 2
35 Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation Completed NCT00315627 Phase 2
36 Diabetic Retinopathy Sulodexide Study Completed NCT01295775 Phase 2
37 Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN). Completed NCT00501202 Phase 2
38 The Effect of Ruboxistaurin on Small Fiber Function Completed NCT00190970 Phase 2
39 Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema Recruiting NCT03161652 Phase 2
40 Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression Active, not recruiting NCT00306098 Phase 2
41 Inflammation Inhibition in Prediabetic Humans Active, not recruiting NCT01977417 Phase 2
42 Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus Terminated NCT00315614 Phase 2
43 A Study Assessing Efficacy and Safety of OC-10X in the Treatment of PDR Terminated NCT02735369 Phase 2
44 Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus Unknown status NCT01319734 Phase 1
45 Umbilical Cord Mesenchymal Stem Cells Infusion for Diabetes Related Vascular Complications Recruiting NCT02834858 Phase 1
46 A Clinical Study Using Autologous Bone Marrow Stem Cell for Diabetes Related Vascular Complications Recruiting NCT02796079 Phase 1
47 A Clinical Study Using Adipose-derived Stem Cells for Diabetic Foot Recruiting NCT02831075 Phase 1
48 Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines Unknown status NCT01974544
49 A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China Unknown status NCT01307410
50 Correlation Between Vitamin D Levels to ADAMTS13 , VWF and Micro RNA Expression in Diabetic Hemodialysis Patients Unknown status NCT02245633

Search NIH Clinical Center for Microvascular Complications of Diabetes 2

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Microvascular Complications of Diabetes 2

Genetic tests related to Microvascular Complications of Diabetes 2:

id Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 2 29

Anatomical Context for Microvascular Complications of Diabetes 2

Publications for Microvascular Complications of Diabetes 2

Variations for Microvascular Complications of Diabetes 2

ClinVar genetic disease variations for Microvascular Complications of Diabetes 2:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 EPO NM_000799.2(EPO): c.-1306C> A single nucleotide variant risk factor rs1617640 GRCh37 Chromosome 7, 100317298: 100317298

Expression for Microvascular Complications of Diabetes 2

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 2.

Pathways for Microvascular Complications of Diabetes 2

GO Terms for Microvascular Complications of Diabetes 2

Sources for Microvascular Complications of Diabetes 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....